MYD88 L265P uncommon in PTLD. Standard PTLD ladder (RIS → rituximab → R-CHOP) per usual a...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-MYD88-L265P-PTLD |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PTLD |
| Sources | SRC-CIVIC SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-MYD88-L265P |
|---|---|
| Variant | L265P |
| Disease | DIS-PTLD |
| ESCAT tier | IV |
| Evidence summary | MYD88 L265P uncommon in PTLD. Standard PTLD ladder (RIS → rituximab → R-CHOP) per usual algorithm; BTKi off-label R/R consideration. |
Notes
ESCAT IV.
Used By
No reverse references found in the YAML corpus.